Ombrabulin is primarily used in the field of oncology as a vascular disrupting agent. It targets and disrupts the blood vessels that supply tumors, effectively cutting off their nutrient and oxygen supply. This leads to the death of cancer cells and shrinkage of tumors. It is often investigated in combination with other chemotherapy agents to enhance its efficacy in treating various types of cancers, such as soft tissue sarcoma and ovarian cancer. Its ability to selectively damage tumor vasculature makes it a promising candidate for improving cancer treatment outcomes.